anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cells, esp. haematopoietic cells, which are trapped with regard to activation, by an antigen (Ag), against which tolerance of the host (animal or human) immune system is sought, contain a genetic sequence (I), the expression product (II) of which, when produced at a high level in the cells, reacts in situ with a pharmaceutically active substance (III) to induce cell destruction. The cell also includes elements, specifically induced by an activation signal provided by Ag, so as to cause high level prodn. of (II). Pref. (I) and the necessary control elements are present on a recombinant DNA fragment specifically, the elements are those which normally control expression of a cytokine (esp. IL-2) or the corresponding receptor. (III) cause, directly or indirectly, interruption of cellular DNA replication.
Accurate myocardial segmentation is crucial in the diagnosis and treatment of myocardial infarction (MI), especially in Late Gadolinium Enhancement (LGE) cardiac magnetic resonance (CMR) images, where the infarcted myocardium exhibits a greater brightness. However, segmentation annotations for LGE images are usually not available. Although knowledge gained from CMR images of other modalities with ample annotations, such as balanced-Steady State Free Precession (bSSFP), can be transferred to the LGE images, the difference in image distribution between the two modalities (i.e., domain shift) usually results in a significant degradation in model performance. To alleviate this, an end-to-end Variational autoencoder based feature Alignment Module Combining Explicit and Implicit features (VAMCEI) is proposed. We first re-derive the Kullback-Leibler (KL) divergence between the posterior distributions of the two domains as a measure of the global distribution distance. Second, we calculate the prototype contrastive loss between the two domains, bringing closer the prototypes of the same category across domains and pushing away the prototypes of different categories within or across domains. Finally, a domain discriminator is added to the output space, which indirectly aligns the feature distribution and forces the extracted features to be more favorable for segmentation. In addition, by combining CycleGAN and VAMCEI, we propose a more refined multi-stage unsupervised domain adaptation (UDA) framework for myocardial structure segmentation. We conduct extensive experiments on the MSCMRSeg 2019, MyoPS 2020 and MM-WHS 2017 datasets. The experimental results demonstrate that our framework achieves superior performances than state-of-the-art methods.
The present invention can inhibit the occurrence of defective products without increasing the hardness of a tablet even if stress is applied to the tablet on transporting it or packing it by an automatic dispensing machine or when taking it out of the PTP and besides can be put into practice easily and inexpensively to result in facilitating the improvement of the productivity. A  tablet according to the present invention comprises a body portion (2) and cap portions (3) projecting from an upper and a lower surfaces (4) from the body portion (2) each in a convex shape. The cap portion (3) has a peripheral edge portion (7) a surface of which is provided with an upright angle (.alpha.) of 35 to 50 degrees with respect to the upper and lower surfaces (4) of the body portion (2) and is formed in a convex curved surface which becomes arcuate in vertical section. The cap portion (3) has its surface provided with an angle (.beta.) of at least 20 degrees with respect to the upper and lower surfaces (4) at a position (9) recessed by a 5%  length (L) of a horizontal length (D) of the body portion (2) from a peripheral edge portion of the body portion (2). The peripheral edge portion (7) has its surface connected to the surface at the mid portion (6) smoothly.
Patients in this arm will receive the Erector Spinae Plane Block (ESP) before awakening from lumbar vertebra surgery. Patients in this arm will receive the Erector Spinae Plane Block (ESP) before awakening from lumbar vertebra surgery. A linear ultrasound probe will be placed transversely over the L3 vertebra to visualize the transverse process. A block needle (Stimuplex® Ultra 360®, B-Braun, USA) will be advanced under ultrasound guidance until it contacts the transverse process. After withdrawing the needle by 1 mm, 50 mg (0.25%) bupivacaine will be injected bilaterally.
To provide a novel assembly of heparin and polyamine, an anticoagulant agent consisting of the assembly, an agent composition containing the assembly, a kit for manufacturing the assembly, a sustained release granting agent, a manufacturing method of the assembly, or the like.SOLUTION: [1] An assembly of heparin and linear or branched polyamine having three or more amino groups. [2] An anticoagulant agent consisting of the assembly according to [1]. [3] An agent composition containing the assembly according to [1]. [4] A kit for manufacturing the assembly, containing heparin or a salt thereof, linear or branched polyamine having three or more amino groups or a salt thereof. [5] A sustained release granting agent for adding sustained release property of heparin, containing the linear or branched polyamine having three or more amino groups or a salt thereof. [6] A manufacturing method of the assembly including mixing a solution of heparin or a salt thereof, and a solution of the linear or branched polyamine having three or more amino groups or a salt thereof.SELECTED DRAWING: Figure 3
Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
The invention discloses a gene editing system and application thereof in constructing a psoriasis model pig nuclear transplantation donor cell with TNIP1 gene mutation. The present invention provides a polypeptide comprising SEQ ID NO:16, TNIP1-gRNA2 shown in SEQ ID NO:17, and the TNIP1-gRNA3 and NCN protein. The invention also provides a method for preparing the recombinant porcine cells, which comprises the following steps: co-transfecting the TNIP1-gRNA2, the TNIP1-gRNA3 and the NCN protein to a pig cell to obtain a recombinant pig cell. The recombinant porcine cells are recombinant cells with TNIP1 gene mutation. The application of the kit is as follows: preparing a recombinant pig cell; preparing a psoriasis model pig; preparing a psoriasis cell model or a psoriasis tissue model or a psoriasis organ model. The invention has great application value for researching and developing the psoriasis medicament and disclosing the pathogenesis of the psoriasis medicament.
Purpose: The aim of this study is to evaluate the possible benefits of using video consent in the preoperative ureteroscopy (URS) consent process. Material and Methods: Prospective randomized trials took place at two Italian tertiary-care centers from March 2022 to September 2022. Patients were randomly assigned to two groups: Group A (standard verbal/written informed consent) and Group B (informed consent supported by video). We investigated the impact of both types of informed consent on patient anxiety levels using the Spielberger State-Trait Anxiety Inventory (STAI) questionnaire both pre- and post-consent. In addition, using the Visual Analogue Scale, analysis of the effect of informed consent on postoperative pain and the number of calls for assistance during hospitalization as secondary outcomes was done. To assess the satisfaction level related to the whole process, patients were asked to rate their experience on a scale of 1-10, with 1 indicating "not satisfied" and 10 indicating "completely satisfied." Results: Overall, 166 patients were randomized 1:1 in each group. The multivariable regression model demonstrated that video-assisted informed consent significantly increased the difference between post- and pre-consent STAI with a reduced level of anxiety. The video-assisted informed consent significantly predicted the number of assistance calls during hospitalization. Conclusions: Video consent for ureteroscopies is a valid tool to improve procedure awareness and satisfaction. Video consent is able to reduce procedure-related patient anxiety and postoperative assistance calls, thus proving to be useful in obtaining better-informed consent for endourological procedures.
Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
1. Process for preparing a solid mixture comprising one or more cyclodextrins and one or more active ingredients wherein said process encompasses a melt-extrusion step, comprising the following substeps: a) mixing one or more cyclodextrins with one or more active ingredients, and b) optionally mixing additives; c) heating the thus obtained mixture until melting of one of the components; d) forcing the thus obtained mixture through one or more nozzles; e) cooling the mixture till it solidifies. 2. A process according to claim 1 which is performed on a twin-screw extruder. 3. A process according to claim 1 or claim 2 wherein the active ingredient is insoluble. 4. A process according to any one of claims 1 to 3 wherein the melt extrudate is milled to a powdered form. 5. A solid mixture comprising one or more cyclodextrins and one or more active ingredients obtainable by the process according to claim 1 wherein the active ingredient is embedded into the cyclodextrin. 6. A solid mixture according to claim 5 that is in amorphous form or in the form of a solid solution. 7. A solid mixture according to claim 5 cyclodextrin is hydroxypropyl-.beta.-cyclodextrin or dimethyl-.beta.-cyclodextrin. 8. A solid mixture according to claim 5 wherein the active ingredient is itraconazole. 9. A pharmaceutical composition comprising a therapeutically effective amount of melt extrudate produced according to claim 1 and other excipients. 10. A pharmaceutical composition comprising a therapeutically effective amount of mlled melt extrudate produced according to claim 4 and other excipients.
The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
PROBLEM TO BE SOLVED: To obtain a diabetes diagnostic effective even if intended for patients with light diabetes, slight in burden on subjects, and instantaneously affording an accurate test result, by including a specific fatty acid. SOLUTION: This diagnostic is obtained by including a fatty acid with at least one carbon atom on specific site labeled with<13> C; wherein the fatty acid is pref. acetic acid, octanoic acid, palmitic acid, oleic acid, linoleic acid, linolenic acid. The test using this diagnostic is such an exhalation test that a subject is administered with this diagnostic either singly or continually, and an increment in the<13> C concentration of exhaled CO2 after the administration is determined. Specifically, the<13> C concentration of the exhaled CO2 following administration is measured, and the aimed diagnosis of diabetes is conducted on the basis of data such as the increment in the<13> C concentration of exhaled CO2 [Δ<13> (%)] after the lapse of a given time following the administration (e.g. 5 min, 10 min, 15 min).
Disclosed is a method for inhibiting the binding of an arenavirus to a cellular receptor. The method involves providing, in soluble form, a reagent comprising α-dystroglycan or a portion thereof, the reagent being characterized by the ability to bind to the arenavirus thereby inhibiting the binding of the arenavirus to the cellular receptor. The reagent is contacted with an arenavirus particle prior to infection of a cell by the arenavirus particle. Also disclosed are methods for treating an arenavirus infection in a patient and preventing an arenavirus infection in an individual at risk. These methods involve providing a therapeutic composition comprising α-dystroglycan or a portion thereof which is characterized by the ability to bind to arenaviruses, thereby inhibiting the binding of arenaviruses to a cellular receptor; and administering the composition to the patient or individual at risk. Arenaviruses to which the methods of the present invention apply include, without limitation, Lymphocyte Choriomeningitis Virus, Lassa fever virus, Mobala, and Oliveros. In another aspect, the disclosure relates to an embryonic stem cell line, and cells derived therefrom, which is homozygous for a disrupted dystroglycan gene, wherein the disruption prevents the synthesis of functional dystroglycan in the cells. Applications of the dystroglycan null embryonic stem cells include producing dystroglycan or a portion thereof in the cells and also for identifying portions of dystroglycan necessary for arenavirus infection. Also disclosed is a method for identifying antiviral compounds which interfere specifically with the binding of arenavirus and α-dystroglycan, comprising providing a binding assay system for the determination of binding of arenavirus and α-dystroglycan. The candidate antiviral compounds are introduced into the binding assay system and antiviral compounds which substantially inhibit binding of arenavirus to α-dystroglycan are identified.
BACKGROUND: Aging and comorbidities like type 2 diabetes and obesity contribute to the development of chronic systemic inflammation, which impacts the development of heart failure and vascular disease. Increasing evidence suggests a role of pro-inflammatory M1 macrophages in chronic inflammation. A shift of metabolism from mitochondrial oxidation to glycolysis is essential for the activation of the pro-inflammatory M1 phenotype. Thus, reprogramming the macrophage metabolism may alleviate the pro-inflammatory phenotype and protect against cardiovascular diseases. In the present study, we hypothesized that the activation of estrogen receptors leads to the elevation of the mitochondrial deacetylase Sirt3, which supports mitochondrial function and mitigates the pro-inflammatory phenotype in macrophages.
MATERIALS AND METHODS: Experiments were performed using the mouse macrophage cell line RAW264.7, as well as primary male or female murine bone marrow macrophages (BMMs). Macrophages were treated for 24 h with estradiol (E2) or vehicle (dextrin). The effect of E2 on Sirt3 expression was investigated in pro-inflammatory M1, anti-inflammatory/immunoregulatory M2, and naïve M0 macrophages. Mitochondrial respiration was measured by Seahorse assay, and protein expression and acetylation were determined by western blotting.
RESULTS: E2 treatment upregulated mitochondrial Sirt3, reduced mitochondrial protein acetylation, and increased basal mitochondrial respiration in naïve RAW264.7 macrophages. Similar effects on Sirt3 expression and mitochondrial protein acetylation were observed in primary female but not in male murine BMMs. Although E2 upregulated Sirt3 in naïve M0, pro-inflammatory M1, and anti-inflammatory/immunoregulatory M2 macrophages, it reduced superoxide dismutase 2 acetylation and suppressed mitochondrial reactive oxygen species formation only in pro-inflammatory M1 macrophages. E2 alleviated the pro-inflammatory phenotype in M1 RAW264.7 cells.
CONCLUSIONS: The study suggests that E2 treatment upregulates Sirt3 expression in macrophages. In primary BMMs, female-specific Sirt3 upregulation was observed. The Sirt3 upregulation was accompanied by mitochondrial protein deacetylation and the alleviation of the oxidative and pro-inflammatory phenotype in M1 macrophages. Thus, the E2-Sirt3 axis might be used in a therapeutic strategy to fight chronic systemic inflammation and prevent the development of inflammation-linked diseases.
The efficacy of NETSPOT was established in three open label single center studies (Study A-C).

In Study A, 97 adult patients (mean age 54; 41 men and 56 women) with known or suspected neuroendocrine tumors (NETs) were evaluated with gallium Ga 68 dotatate PET. The gallium Ga 68 dotatate images were read by two independent readers blinded to clinical information. The reads were compared to CT and/or MR images and to indium In 111 pentetreotide images obtained with Single Photon Emission Computed Tomography (SPECT) within previous 3 years. Among 78 patients in whom CT and/or MR images and indium In 111 pentetreotide images were available, gallium Ga 68 dotatate PET was in agreement with the CT and/or MR images in 74 patients. Out of 50 patients with NETs localized by CT and/or MR imaging, gallium Ga 68 dotatate was positive in 48 patients, including 13 patients in whom indium In 111 pentetreotide was negative. Gallium Ga 68 dotatate was negative in 26 out of 28 patients in whom CT and/or MR imaging was negative.

Study B was a published study which involved 104 patients (mean age 58; 52 men and 52 women) with suspected NETs due to clinical symptoms, elevated levels of tumor markers, or indeterminate tumors suggestive of NET. Diagnostic performance of gallium Ga 68 dotatate PET in localizing tumor sites was retrospectively assessed using a reference standard: histopathology (n = 49) or clinical follow up of up to 5-month duration (n = 55). Images were interpreted by consensus between two on-site readers who were not blinded to clinical information. NET sites were localized by reference standard in 36 patients (all by histopathology). Out of these, gallium Ga 68 dotatate was positive, correctly identifying an NET site, in 29 patients and was falsely negative in seven. In 68 patients with no NET identified by a reference standard, the images were negative in 61 and falsely positive in seven patients.

Study C was a published study which involved 63 patients (mean age 58; 34 men and 29 women) evaluated for NET recurrence using a reference standard as described for Study B. Gallium Ga 68 dotatate images were interpreted independently by two central readers blinded to clinical information. Reader 1 correctly localized NETs in 23 out of 29 reference standard-positive patients and reader 2 correctly localized NETs in 22 such patients. In 34 patients with no NET identified by a reference standard, reader 1 was correct in 29 patients and reader 2 in 32.
Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
The invention consists of two formulas, Dr. Lord's Olive Leaf Tea Formula (Anti-Covid-19 Tea Formula) and the Energy Elixir. Both formulas are unique combinations of plants that have been proven to combat and provide relief from viruses, flu symptoms, itchy and sore throat. My invention is specially formulated to work fast, provide fast relief, in a matter of 20-30 minutes in most cases. One should use promptly when feeling the beginning, the onset of these symptoms. My invention, these formulas, work well together to facilitate speedy system recovery and functionality. The olive leaf tea formula is in loose tea form and the Energy Elixir is in liquid form.
FIELD: veterinary science. SUBSTANCE: blood is let from examined animal and blood smears are applied to slides. Specifically labelled adsorbed serum containing fluorescent antibody is applied. Smears are examined in luminescent microscope. Antigen-containing cells are identified by nature and intensity of luminescence of cells of system of mononuclear phagocytes. Index of immunofluorescence is calculated by division of number of fluorescent sells of mononuclear phagocytes by the number of examined fields of vision and if obtained value equals 0.2-0.4, the animals are considered ill. EFFECT: higher efficiency. 2 tbl
In all clinical trials including over 6,200 patients, more than 2,700 patients were exposed to combinations of aliskiren and HCTZ. The safety and efficacy of Tekturna HCT were evaluated in patients with mild-to-moderate hypertension in an 8-week, randomized, double-blind, placebo-controlled, parallel-group, 15-arm factorial trial (n=2762). Patients were randomized to receive various combinations of aliskiren (75 mg to 300 mg) plus HCTZ (6.25 mg to 25 mg) once daily (without titrating up from monotherapy) and followed for blood pressure response. The combination of aliskiren and HCTZ resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressure at trough of 10–14/5–7 mmHg at doses of 150–300 mg/12.5–25 mg, compared to 5–8/2–3 mmHg for aliskiren 150 mg to 300 mg and 6–7/2–3 mmHg for HCTZ 12.5 mg to 25 mg, alone. Blood pressure reductions with the combinations were greater than the reductions with the monotherapies as shown in Table 1. 

The safety and efficacy of Tekturna HCT as initial therapy was evaluated in this trial. All patients randomized to the combination groups received the combination treatment of Tekturna HCT at assigned doses as initial therapy without titration from monotherapy. The figures [see Indications and Usage ( 1)]  display the probability that a patient will achieve systolic or diastolic blood pressure goal with Tekturna HCT 300/25 mg, based upon their baseline systolic or diastolic blood pressure. At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. 

The antihypertensive effect of Tekturna HCT was largely manifested within 1 week. The maximum antihypertensive effect was generally attained after about 4 weeks of therapy. 

One active-controlled trial investigated the addition of 300 mg aliskiren in obese hypertensive patients who did not respond adequately to HCTZ 25 mg, and showed incremental decreases of systolic and diastolic blood pressure of approximately 7/4 mmHg. 

In long-term follow-up studies (without placebo control) the effect of the combination of aliskiren and HCTZ was maintained for over 1 year. 

The antihypertensive effect was independent of age and gender. There were too few non-Caucasians to assess differences in blood pressure effects by race.